WO2006135084A1 - Agent prophylactique ou thérapeutique pour stéatohépatite ou foie adipeux - Google Patents

Agent prophylactique ou thérapeutique pour stéatohépatite ou foie adipeux Download PDF

Info

Publication number
WO2006135084A1
WO2006135084A1 PCT/JP2006/312209 JP2006312209W WO2006135084A1 WO 2006135084 A1 WO2006135084 A1 WO 2006135084A1 JP 2006312209 W JP2006312209 W JP 2006312209W WO 2006135084 A1 WO2006135084 A1 WO 2006135084A1
Authority
WO
WIPO (PCT)
Prior art keywords
luteolin
steatohepatitis
food
fatty liver
glycoside
Prior art date
Application number
PCT/JP2006/312209
Other languages
English (en)
Japanese (ja)
Inventor
Hironori Koga
Original Assignee
Kurume University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kurume University filed Critical Kurume University
Priority to JP2007521373A priority Critical patent/JPWO2006135084A1/ja
Publication of WO2006135084A1 publication Critical patent/WO2006135084A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/06—Benzopyran radicals
    • C07H17/065—Benzo[b]pyrans
    • C07H17/07—Benzo[b]pyran-4-ones

Definitions

  • the present invention relates to a medicament for preventing or treating steatohepatitis, particularly non-alcoholic steatohepatitis, or fatty liver, and a food or drink for preventing or ameliorating these diseases.
  • the main causes of fatty liver a condition in which neutral fat accumulates in the liver, are obesity, excessive consumption of alcohol, and diabetes.
  • the liver synthesizes neutral fats from dietary fats and carbohydrates, and these neutral fats bind to proteins and enter blood vessels from the liver and are mainly used as energy sources.
  • neutral fat When neutral fat is synthesized beyond that capacity, neutral fat accumulates in hepatocytes and becomes fatty liver.
  • diagnosis is performed mainly by ultrasonography and partly by CT, triggered by mild abnormal liver function.
  • NASH Non-alcoholic steatohepati tis
  • luteolin 3 , 4, 4 ', 5, 7 -tetrahydroxy flavone
  • glycoside which is a natural product contained in celery, peppers, spring chrysanthemum, chamomile, shiso, etc. (3, one-dalk mouth, 6-C-fucoside, 6-C-quinoside, 7-O-rutinoside, etc.) are known to show various medicinal effects.
  • Japanese Patent Application Laid-Open No. 5_4 3 4 6 9 discloses that luteolin 1,3, 1 dalcuronide and the like reduce diarrhea induced by camptothecin, which is an antitumor agent.
  • HEI 7-3 33 7 discloses that luteolin, luteolin and luteolin 1 3′-dalcronide have UDP-dalcronyl transferase inhibitory activity.
  • 7-Rutinoside and other external preparations are disclosed in Japanese Patent Application Laid-Open No. Hei 10-2 9 8 98 98, in which luteolin or the like obtained from egoma or perilla seeds or defatted seeds has a lipoxygenase inhibitory action
  • Japanese Patent Application Laid-Open No. 2 00 0-8 6 5 1 0 discloses that seeds of egoma and perilla or the like thereof are effective in preventing or treating allergic diseases, inflammation, circulatory system diseases or cancer metastasis. Obtained from defatted seed Etc.
  • Teorin for example, a medicament for the prevention and treatment of allergic diseases, quasi In Japanese Patent Application Laid-Open No. 2000-0 2 3 9 1 3 6, luteolin obtained from perilla and pegoma seeds or leaves against oral bacteria, It has excellent antibacterial activity and can be applied to foods and drinks and oral products as an oral antibacterial agent.
  • JP-A-2001-1 1 46 7 5 discloses that flavonoids such as vitamin K and luteo 5 phosphorus
  • JP-A No. 2000-11075 3 discloses that a composition containing a mixture of aldehydes has an amylase inhibitory action, such as luteolin obtained from an olive leaf, an amylase inhibitor, and a blood sugar level increase inhibitor.
  • Japanese Patent Application Laid-Open No. 20 0-2 2 5 5 7 78 describes that luteolin 7-glycoside and the like can be used in light citral products by light. Citral reduction or 0 for the control of citral-derived odors
  • Japanese Patent Application Laid-Open No. 2003-34071 discloses that since luteolin itself has an antitumor action, it can be used together with a speridine glycoside agent for antitumor activity.
  • No. 00 3-1 2 8 5 5 8 discloses that luteolin-O-rutinoside can be used as a therapeutic agent for allergic rhinitis and as a food for preventing allergy by adding the therapeutic agent to food.
  • JP-A 2 0 0 5-7 5 7 6 6 discloses that it is possible to suppress amide formation, as an endothelin-1 production inhibitor containing luteolin and Z or a glycoside thereof as heart disease or As an antihypertensive agent, it is added to various 5 foods and added as a food for specified health use or as a functional food, and it is added to pet food, feed, etc. to improve the heart disease and hypertension of pet animals. Or can be used as a cosmetic for whitening by adding to cosmetics, and Japanese Patent Application Laid-Open No.
  • a lipoxygenase inhibitor comprising a fermented product luteolin content fermented until 1 0 0 X 1 0- 5 wt % or more as a fermented product of Nigana plants, inflammatory and allergic conditions, cardiovascular disease, It also describes that it can be applied to hair growth inhibitory or hair removal regulators or cosmetic compositions.
  • the composition containing isoflavone is hepatic steatosis, steatohepatitis, insulin resistance, impaired glucose tolerance, X syndrome Disclosed are methods for treating or preventing abnormal platelet function or abnormal vascular responsiveness.
  • the isobrabons include genistin derived from soybean, genistin, 6, 1-O-malonyl genistin, 6, 0-acetinoregestin; daidzein, daiddin, 6, 1 O-malonic Noredidodine, 6 ,, 1 O-acetylgenistin; Glycitin, Glycytin, 6 ,, 1 O—Maroninoreglycitin, 6, '1 O-acetylinoreglicity, B iochanin A, or formononetin Yes.
  • An object of the present invention is to provide a medicament for preventing or treating steatohepatitis, particularly non-alcoholic steatohepatitis, or fatty liver, and food and drink for preventing or ameliorating these diseases.
  • the present invention is as follows.
  • the preventive or therapeutic agent according to any one of (1) to (3) above, and the prophylactic or therapeutic agent are used for the prevention or treatment of steatohepatitis or nonalcoholic steatohepatitis or fatty liver.
  • a food or drink containing luteolin and / or its glycoside that prevents or improves fatty liver is a food or drink containing luteolin and / or its glycoside that prevents or improves fatty liver.
  • a method for preventing or treating steatohepatitis, non-alcoholic steatohepatitis or fatty liver comprising administering to a subject an effective amount of luteolin and / or its glycoside.
  • a fatty liver inhibitor comprising luteolin and / or a glycoside thereof as an active ingredient.
  • Fig. 1 is a graph showing the effects of improving choline deficiency, high fat, and low protein diets on mouse fatty liver and Z or steatohepatitis.
  • A shows the liver histology of the group not administered with luteolin
  • B shows the liver histology of the group administered with luteolin.
  • FIG. 2 is a western blot diagram showing the expression of proteins derived from liver tissue in the group not administered with luteolin and in the group administered with luteolin.
  • lanes 1 and 2 are phosphorylated (Tyr 705 ) STAT3
  • lanes 3 and 4 are STAT3
  • lanes 5 and 6 are SREBPlc
  • lanes 7 and 8 are FAS
  • odd lanes are not treated with luteolin
  • the even lanes indicate the luteolin administration group.
  • the present invention relates to a preventive or therapeutic agent for steatohepatitis or non-alcoholic steatohepatitis or fatty liver, which contains luteolin and / or its glycoside.
  • the present invention also provides the preventive or therapeutic agent, and the preventive or therapeutic agent for the prevention or treatment of steatohepatitis or nonalcoholic steatohepatitis or fatty liver.
  • SREBPs Sterol regulatory element-binding proteins
  • SREBP-1 especially SREBP_lc
  • SREBP_lc one of the SREBPs isofo rms
  • FAS fatty acid synthase
  • luteolin which is an active ingredient, can use commercially available products.
  • Various plants for example, celery, peppers, spring chrysanthemum, chamomile, perilla, egoma, pine nuts, etc. where perilla or egoma seeds
  • defatted seeds are particularly preferable.
  • Dyer's Rocket D yer, s Rocket, Weld
  • Synopmox Seiso, Moxeiso, and Kudamonotokeisou (Phytochemistry, 30, 3486, 1991).
  • it was isolated and purified from a fermented product obtained by fermenting the Japanese algae plant disclosed in Japanese Patent Laid-Open No. 2 0 5-8 8 9 3 8 5 until the luteolin content was 10 0 X 10 0 " 5 wt% or more.
  • the luteolin glycoside which is an active ingredient that can be used in the present invention, is a naturally occurring glycoside of luteolin and a sugar (eg, glucose, fucose, galactose, 6-deoxydarcos).
  • the sugar binding position is, for example, 6-C, 8-C, 7-0, or 4′_0 of the luteolin molecule, and the preferred luteolin glycoside is luteolin-6-C-darco. Sid.
  • 3′-dalclonide, 6-C-fucoside, 6-C-quinoside, 7-0-rutinoside and the like can also be used.
  • Luteolin and luteolin glycosides can be isolated as follows. Isolation from a plant containing luteolin and its glycosides can be done by pulverizing the whole plant or a part of the roots, stems, leaves, flowers, fruits, seeds, etc. with a mixer, etc., followed by water, ethanol, Stir in an extraction solvent such as methanol or ethyl acetate (extraction solvents can be used alone or in combination of two or more), and remove insolubles by centrifugation or filtration. The clear or filtrate is appropriately dried under reduced pressure and can be carried out by a conventional method (such as force chromatography).
  • an extract of any plant can be used as long as it contains luteolin and / or its glycoside, and examples thereof include cerebral family plants such as blue dissociation, red dissociation and egoma, seri and assipac
  • cerebral family plants such as blue dissociation, red dissociation and egoma, seri and assipac
  • vegetables such as celery, lettuce, spring chrysanthemum, and peppers, soybean leaves, pinnacle seed coat, yew, honeysuckle, western cherry, chamomile, and peppermint
  • extracts such as Kudamono Tokeisou it can.
  • flavonoids In general, naturally occurring flavonoids often take the form of glycosides, but perilla seeds contain a large amount of aglycone-like luteolin. Since aglycone is known to have stronger antioxidant activity than glycoside (Biochemical Medicine and Metabolic Biology, 39, 69, 1988), prevention or treatment of steatohepatitis or nonalcoholic steatohepatitis It is desirable to use luteolin that is purified from plant seeds that are rich in aglycone. In particular, extraction from the seeds of Lamiaceae plants such as blue dissociation, red dissociation and sesame is preferred. It is more preferable to use a defatted seed as the seed.
  • the prophylactic or therapeutic agent for steatohepatitis or nonalcoholic steatohepatitis or fatty liver containing luteolin and / or its glycoside is luteolin and / or its glycoside itself. However, it is formulated into a dosage form such as tablets, powders, emulsions, capsules, injections, drops, external preparations, etc., by a commonly used solid or liquid carrier, emulsion powder, etc. Also good.
  • a carrier Water, gelatin, starch, ratatoose, hydroxypropylcellulose, hydroxymethylcellulose, magnesium stearate, talc, vegetable oil, etc., including pharmaceutically acceptable dyes, preservatives, stabilizers, etc. Can be added.
  • the prophylactic or therapeutic drug for steatohepatitis or non-alcoholic steatohepatitis, or fatty liver may contain other active ingredients within a range where contraindications can be avoided, and at the same time or at intervals with other drugs. Can be used.
  • the content of luteolin and z or glycoside thereof in the preventive or therapeutic agent for steatohepatitis or non-alcoholic steatohepatitis of the present invention or fatty liver is appropriately changed depending on the purpose of administration, administration route, dosage form For example, it is 0.05 to 1% by weight based on the total weight of the preparation.
  • the dosage of the prophylactic or therapeutic drug for steatohepatitis or non-alcoholic steatohepatitis or fatty liver of the present invention is not particularly limited.
  • the type of illness, patient age, sex, weight, symptoms It can be determined appropriately according to the degree of administration or the administration method.
  • the dosage when orally administered to male adults, is preferably 0.01 mg / kg to 10,000 mg / kg per day, and can be administered once or divided into several times a day.
  • the dose is more preferably 0.1 mg / kg to 1000 mg / kg, and even more preferably 0.5 mg / kg to 500 mg / kg.
  • the present invention also relates to a food or drink containing the luteolin and / or glycoside thereof.
  • the food and drink of the present invention is taken for the purpose of preventing or improving steatohepatitis, particularly non-alcoholic steatohepatitis or fatty liver.
  • the food and drink of the present invention includes foods and beverages, for example, health foods including specified health foods and functional foods, and general foods including so-called health foods such as dietary supplements. Can be given. Forms can be added to milk drinks, juices, sports drinks, Japanese tea, oolong tea, coffee, tea, diet drinks, Japanese confectionery, Western confectionery, bread, ice cream, sorbet, hamburger, pizza and the like. .
  • steatohepatitis, non-alcohol It can be labeled as being used to prevent or ameliorate fatty steatohepatitis or fatty liver.
  • a display method preferably, a method described in the packaging material of the food or drink, a method of displaying as an attached document on the food or drink, and the like are given.
  • the content of luteolin and Z or a glycoside thereof contained in the food or drink of the present invention is not particularly limited.
  • the amount of the active ingredient ingested from the food or drink of the present invention can be appropriately determined according to the purpose of ingestion, the age, sex, body weight, symptom level, etc. of the subject.
  • the intake is preferably 0.01 rag / kg to 10,000 mg / kg per day, and can be taken once or several times a day.
  • the intake is more preferably from 0.5 ltng / kg to 1000 mg / kg, and even more preferably from 0.5 mg / kg to 500 rag / kg.
  • the chemicals and foods and drinks of the present invention can be ingested by animals other than humans, for example, pets such as dogs, cats, hamsters, monkeys, etc. as veterinary medicines or in feeds.
  • an inhibitor of fatty liver containing luteolin opi Z or a glycoside thereof as an active ingredient is provided.
  • the fatty liver inhibitor of the present invention can be used as a research reagent or a food or drink additive, but is preferably used for food or drink addition.
  • the content of luteolin and no or glycoside thereof contained in the fatty liver inhibitor of the present invention is not particularly limited, but is usually from 0.05 to 10% by weight, preferably from 0.001 to 1% by weight, more preferably 0.05 to 100% by weight. It is desirable to contain / 0 . ..
  • the inhibitor of fatty liver of the present invention may contain a carrier.
  • a carrier examples include water, gelatin, starch, ratatoose, hydroxypropinolecellulose, hydroxymethylcellulose, magnesium stearate, talc, vegetable oil, etc., which are acceptable for food hygiene, preservatives, Adjuvants such as stabilizers can be added.
  • mice were given a choline-deficient 'high fat' low protein diet (choline-deficient diet, CLEA Japan, Inc.) for 10 weeks to develop fatty liver and Z or steatohepatitis.
  • Comparison was also made with syngeneic mice (n 3) fed a normal diet (CE-2; Nippon Claire Co., Ltd.).
  • luteolin administration group 97.2% pure luteolin extracted and purified from perilla seeds was dissolved in dimethyl sulfoxide (DMS0) and adjusted so that the final concentration in the feed water was about 200 ppm ( At this time, some precipitates may be formed).
  • the luteolin-containing water was changed every other day.
  • the liver tissue was collected and a sample was prepared.
  • the body weight of mice fed choline deficient, high fat, and low protein diets was slightly lighter than the normal diet group (31. 1), but there was no difference in body weight between the luteolin administration group and the luteolin non-administration group. The average was 29.2 g.
  • liver of mice not treated with luteolin was swollen and macroscopically yellowish.
  • the liver weight was 2.23 g in the luteolin non-administered group and 1.86 g in the luteolin-administered group, and the increase in liver weight was suppressed in the luteolin-administered group (the liver weight in the normal diet group was 1.84 g).
  • fatty degeneration with large lipid droplets was clearly observed in the liver tissue hepatocytes of the group not administered with luteolin, and infiltration of inflammatory cells was also observed. These histological changes were considered to be the cause of hepatomegaly and increased liver weight.
  • a safe and effective drug for the prevention or treatment of steatohepatitis or non-alcoholic steatohepatitis or fatty liver is provided.
  • food and drink that prevent or ameliorate fatty hepatitis or non-alcoholic steatohepatitis, which is highly safe and effective, is provided.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

L’invention concerne un médicament de prévention ou de traitement de la stéatohépatite, et en particulier de la stéatohépatite non alcoolique ou foie adipeux et une boisson/aliment pour la prévention ou l’amélioration de cette maladie. Elle décrit un agent prophylactique ou thérapeutique de la stéatohépatite, de la stéatohépatite non alcoolique ou du foie adipeux qui comprend de la lutéoline et/ou un de ses glucosides ; et une boisson/aliment pour la prévention ou l’amélioration de la stéatohépatite, de la stéatohépatite non alcoolique ou du foie adipeux qui comprend de la lutéoline et/ou un de ses glucosides, de préférence une boisson/aliment qui porte une étiquette sur laquelle se lisent les mots « ce produit est destiné à être utilisé pour la prévention ou l’amélioration de la maladie. »
PCT/JP2006/312209 2005-06-14 2006-06-13 Agent prophylactique ou thérapeutique pour stéatohépatite ou foie adipeux WO2006135084A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2007521373A JPWO2006135084A1 (ja) 2005-06-14 2006-06-13 脂肪性肝炎または脂肪肝の予防または治療薬

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005-173813 2005-06-14
JP2005173813 2005-06-14

Publications (1)

Publication Number Publication Date
WO2006135084A1 true WO2006135084A1 (fr) 2006-12-21

Family

ID=37532430

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2006/312209 WO2006135084A1 (fr) 2005-06-14 2006-06-13 Agent prophylactique ou thérapeutique pour stéatohépatite ou foie adipeux

Country Status (2)

Country Link
JP (1) JPWO2006135084A1 (fr)
WO (1) WO2006135084A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011037738A (ja) * 2009-08-08 2011-02-24 Chube Univ 難聴又は耳鳴りの予防・治療剤
JP2011236133A (ja) * 2010-05-06 2011-11-24 Nippon Tablet Kk キサンチンオキシダーゼ阻害剤、キサンチンオキシダーゼ阻害活性及び５α−レダクターゼ阻害活性を有する酵素阻害剤、並びに該酵素阻害剤を含有する飲食品類、化粧料組成物、医薬組成物
CN102552238A (zh) * 2011-12-21 2012-07-11 南京医科大学 木犀草素的新用途
JP2014131967A (ja) * 2013-01-04 2014-07-17 Nagase & Co Ltd 美白用皮膚外用組成物
JP2014132894A (ja) * 2012-12-11 2014-07-24 Ikeda Shokken Kk セリ科植物エキスの製造方法
JP2018534323A (ja) * 2015-11-19 2018-11-22 シニュー・ファーマ・インコーポレイテッドＳｉＮｅｗ Ｐｈａｒｍａ Ｉｎｃ． 脂肪肝の予防または処置用医薬組成物
JP2020074729A (ja) * 2018-11-09 2020-05-21 株式会社東洋発酵 脳機能改善組成物

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6442427A (en) * 1987-08-10 1989-02-14 Tsumura & Co Sialidase inhibitor
JPH0761927A (ja) * 1993-08-25 1995-03-07 Lotte Co Ltd リパーゼ阻害剤およびこれを添加した飲食品
JPH09143070A (ja) * 1995-09-22 1997-06-03 Nippon Flour Mills Co Ltd リパーゼ阻害剤及び血中トリグリセライド低下剤
JPH09194390A (ja) * 1996-01-18 1997-07-29 Nisshin Flour Milling Co Ltd 内臓脂肪蓄積抑制剤
JP2002010753A (ja) * 2000-04-24 2002-01-15 Marukin Chuyu Co Ltd オリーブ葉またはその抽出成分を含有するアミラーゼ阻害剤および高血糖者用食品
WO2002062365A1 (fr) * 2001-02-01 2002-08-15 Meiji Seika Kaisha, Ltd. Procede de production d'un extrait vegetal de lamiacee contenant des phenols, et utilisation de ce dernier
CN1589804A (zh) * 2003-09-28 2005-03-09 吉林省科学技术信息研究所 一种治疗脂肪肝、肥胖症的中药提取物及其制备方法
JP2005350472A (ja) * 2004-06-10 2005-12-22 Abgenomics Corp ペルオキシソーム増殖因子活性化受容体の調節

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6442427A (en) * 1987-08-10 1989-02-14 Tsumura & Co Sialidase inhibitor
JPH0761927A (ja) * 1993-08-25 1995-03-07 Lotte Co Ltd リパーゼ阻害剤およびこれを添加した飲食品
JPH09143070A (ja) * 1995-09-22 1997-06-03 Nippon Flour Mills Co Ltd リパーゼ阻害剤及び血中トリグリセライド低下剤
JPH09194390A (ja) * 1996-01-18 1997-07-29 Nisshin Flour Milling Co Ltd 内臓脂肪蓄積抑制剤
JP2002010753A (ja) * 2000-04-24 2002-01-15 Marukin Chuyu Co Ltd オリーブ葉またはその抽出成分を含有するアミラーゼ阻害剤および高血糖者用食品
WO2002062365A1 (fr) * 2001-02-01 2002-08-15 Meiji Seika Kaisha, Ltd. Procede de production d'un extrait vegetal de lamiacee contenant des phenols, et utilisation de ce dernier
CN1589804A (zh) * 2003-09-28 2005-03-09 吉林省科学技术信息研究所 一种治疗脂肪肝、肥胖症的中药提取物及其制备方法
JP2005350472A (ja) * 2004-06-10 2005-12-22 Abgenomics Corp ペルオキシソーム増殖因子活性化受容体の調節

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GUILLET-DENIAU I. ET AL.: "Glucose induces de novo lipogenesis in rat muscle satellite cells through a sterol-regulatory-element-binding-protein-1c-dependent pathway", JOURNAL OF CELL SCIENCE, vol. 117, no. 10, 2004, pages 1937 - 1944, XP003003005 *
JANSEN P.L.M.: "Nonalcoholic steatohepatitis", THE NETHERLANDS JOURNAL OF MEDICINE, vol. 62, no. 7, 2004, pages 217 - 224, XP003003007 *
SELVENDIRAN K. ET AL.: "A ubiquitin-dependent degradation of signal transducer and activator of transcription (STAT) 3 is promoted in luteolin-induced apoptosis in human hepatoma cells", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, vol. 46, 2005, pages 722 - 723, XP003003006 *
TSUTSUMI K. ET AL.: "Water extract of defatted rice bran suppresses visceral fat accumulation in rats", JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, vol. 48, no. 5, 2000, pages 1653 - 1656, XP003003004 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011037738A (ja) * 2009-08-08 2011-02-24 Chube Univ 難聴又は耳鳴りの予防・治療剤
JP2011236133A (ja) * 2010-05-06 2011-11-24 Nippon Tablet Kk キサンチンオキシダーゼ阻害剤、キサンチンオキシダーゼ阻害活性及び５α−レダクターゼ阻害活性を有する酵素阻害剤、並びに該酵素阻害剤を含有する飲食品類、化粧料組成物、医薬組成物
CN102552238A (zh) * 2011-12-21 2012-07-11 南京医科大学 木犀草素的新用途
JP2014132894A (ja) * 2012-12-11 2014-07-24 Ikeda Shokken Kk セリ科植物エキスの製造方法
JP2014131967A (ja) * 2013-01-04 2014-07-17 Nagase & Co Ltd 美白用皮膚外用組成物
JP2018534323A (ja) * 2015-11-19 2018-11-22 シニュー・ファーマ・インコーポレイテッドＳｉＮｅｗ Ｐｈａｒｍａ Ｉｎｃ． 脂肪肝の予防または処置用医薬組成物
EP3391881A4 (fr) * 2015-11-19 2020-03-11 Sinew Pharma Inc. Composition pharmaceutique destinée à prévenir et traiter la stéatose hépatique
JP2020074729A (ja) * 2018-11-09 2020-05-21 株式会社東洋発酵 脳機能改善組成物
JP7287638B2 (ja) 2018-11-09 2023-06-06 株式会社東洋発酵 脳機能改善組成物

Also Published As

Publication number Publication date
JPWO2006135084A1 (ja) 2009-01-08

Similar Documents

Publication Publication Date Title
AU2009318456B2 (en) Antioxidant
US20120052138A1 (en) Composition comprising green tea extract
WO2007119837A1 (fr) Inhibiteur de lipase
WO2011077800A1 (fr) Agent permettant d'améliorer une hyperlipémie, composition permettant d'améliorer une anémie, composition permettant de réduire le taux d'acide urique et aliments et boissons
CA2602066A1 (fr) Extrait d'aloes vrai, methode de production d'un extrait d'aloes vrai et agent ameliorant l'hyperglycemie
WO2006135084A1 (fr) Agent prophylactique ou thérapeutique pour stéatohépatite ou foie adipeux
KR101158856B1 (ko) 콩잎 추출물 또는 이의 분획물을 유효성분으로 함유하는 비만, 고지혈증, 동맥경화, 지방간, 당뇨 또는 대사증후군의 예방 또는 치료용 조성물
JP5594819B2 (ja) 脂質代謝改善用組成物
JP2008528483A (ja) 三七根、熟地黄、五加皮の混合生薬材抽出物及びそれを有効成分とする関節炎予防及び治療用組成物
RU2353368C1 (ru) Лекарственное средство и пищевой продукт или напиток для улучшения функций поджелудочной железы
JPWO2006033351A1 (ja) チオレドキシン発現誘導用組成物
KR101672274B1 (ko) 자화지정 추출물 또는 자화지정, 도인, 계지, 및 감초 복합 추출물을 포함하는 지질 관련 심혈관 질환 및 비만의 예방 또는 치료용 조성물
CA2742946C (fr) Antioxydant
JP5619752B2 (ja) パンドラチン誘導体またはボエセンベルギアパンドラタ抽出物の新規な用途
KR20170023910A (ko) 퀘르세틴-3-o-글루코시드를 포함하는 비알콜성 지방간 예방 또는 치료용 약학적 조성물
WO2008150074A2 (fr) Composition comprenant les extraits, les fractions et les composés isolés de rhus verniciflua pour la prévention et le traitement des complications diabétiques
WO2018101231A1 (fr) Composition permettant l'activation du nerf sympathique
JP2003026584A (ja) 肝臓疾患治療剤
JP6105186B2 (ja) 膵リパーゼ阻害剤
KR101695299B1 (ko) 필발 추출물, 이소플라본을 함유하는 대두 추출물 및 ｌ-카르니틴을 함유하는 비만 또는 고지혈증 예방용 또는 개선용 조성물
JP2006193501A (ja) アディポネクチン調節剤、それを含有する飲食品、食品添加物及び医薬
JP2011132147A (ja) 濃縮赤ワインエキスを有効成分とする中性脂肪吸収阻害剤
JP5706142B2 (ja) フユボダイジュ花のエタノール抽出物を有効成分とする血中グルコース低下剤、内臓脂肪蓄積抑制剤、ｔｇ低下剤、糞中脂肪排泄促進剤
WO2006135083A1 (fr) Agent prophylactique ou thérapeutique pour le syndrome métabolique lié à la graisse viscérale
JP2003095941A (ja) 糖質消化酵素阻害剤、血糖値上昇抑制剤、肥満治療予防剤、糖尿病治療予防剤、健康飲食物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2007521373

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06766873

Country of ref document: EP

Kind code of ref document: A1